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Medicines and driving – Evaluation of training and software support for patient 
counselling by pharmacists  
 
 
 
Abstract 
Background: The consumption of some psychotropic medicines has a negative effect on the fitness to 
drive. Pharmacists are expected to give useful advice to patients on their participation in traffic. 
However, almost no information is available on this topic.  
Objective: To assess the effect of training and implementation of new dispensing guidelines with 
regard to driving impairing medicines, in two types of dispensing support tools. User acceptance was 
measured as well as the effect on pharmacists’ attitudes & awareness, self-reported behaviour and 
knowledge. 
Setting: Pharmacists from East Flanders in Belgium. 
Methods: Two intervention groups and a control group participated. The intervention groups followed a 
training and were provided with a dispensing support tool containing information on the effect of 
medicines on driving ability, which was either stand-alone (USB stick) or integrated into the daily used 
software (ViaNova). The three groups filled out a questionnaire prior to and after the intervention 
period.  
Main outcome measure: Answers to a pre/post-questionnaire on attitudes and awareness, self-
reported behaviour, knowledge and user acceptance. 
Results: Many pharmacists were already strongly interested in the topic at the beginning of the study. 
Positive changes in attitude, self-reported behaviour and knowledge were measured mostly in the 
group of pharmacists for which the information was integrated in their daily used software. These 
pharmacists asked significantly more about the patients’ driving experience, informed them more 
about driving-related risk and gave more detailed information on impairing effects of medicines. The 
knowledge of the participating pharmacists on the topic ‘medicines and driving’ remained generally 
low. The participants acknowledge the importance of being aware of the topic medicines and driving 
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but they report a lack of information or education. They strongly prefer a tool that integrates the 
information in their daily used software. 
Conclusion: Dispensing support tools with information on the potential impairing effect of a medicine 
on the fitness to drive increases awareness, reported risk communication behaviour as well as 
knowledge of pharmacists on this topic. Computerised dispensing support tools are most effective 
when the information is integrated into the daily used dispensing software.  
 
Bullet statements (2-5) 
- The present study provides scientific evidence that including risk information into the daily 
used dispensing software can change the counselling behaviour of pharmacists  
- The present study offers future perspectives for optimising the risk communication between 
pharmacists and patients with regard to the topic of medicines and driving  
 
 
Key words: pharmacists, dispensing, software, medicines, driving, risk communication, patients  
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Background 
It is known since many years that the consumption of some psychotropic medicines has a negative 
effect on fitness to drive. Either taken alone or in combination with other substances such as alcohol, 
these medicines increase the risk of having a traffic accident (1-4). The impairing medicinal effects not 
only depend on the active substance in the medicine but also on dose, time interval and indication or 
individual variations. Therefore it is important to inform drivers who use driving-impairing medicines on 
the risk of driving under the influence.  
All psychotropic medicines are provided with a package information leaflet for the patient. 
However, the information it contains does not always provide proper advice for the patient on his/her 
participation in traffic. Healthcare professionals, like physicians and pharmacists, are expected to 
provide such information at the time of prescribing or dispensing a medicine (5). In the past few years 
pharmacists started to play a more central role in providing information to patients when delivering a 
medicine (6-8). The important role of pharmacists in the health information transfer to patients is also 
acknowledged in Belgium. Since April 2010, a new system of remuneration for pharmacists came into 
force. Its objective is to reinforce the intellectual role of the pharmacist and to partly disconnect the 
remuneration based on the price of medicines (9). 
Practitioners admit though that there is a need to use guidelines for safe prescribing and 
dispensing of medicines to patients who operate motor vehicles or other transportation vehicles but 
practical recommendations are not common (10). With regard to pharmacists, such guidelines can 
help them to comply with their (risk communicating) role and allow them to provide more concrete 
information to the patient shortly before administration. Within the European project DRUID (Driving 
Under the Influence of Drugs, alcohol and medicines) prescribing/dispensing guidelines and a 
European medicinal categorisation system were developed. The emphasis of the DRUID dispensing 
guidelines lays on using safer medicines if available, and on improving the warning and counselling of 
patients about the risks and on how to act responsibly when using medicines that have the potential to 
impair driving (11). In order to meet this goal, experts involved in DRUID proposed a four level 
classification and labelling system regarding the influence of a medicine on driving performance, from 
category 0 (no or negligible influence on fitness to drive) to category 3 (major influence on fitness to 
4 
 
drive) (12). The proposed categorisation system was made compatible with existing national labelling 
systems such as in Spain and France. About 1500 medicines were categorised with regard to their 
influence on fitness to drive. 
Moreover, fact sheets were produced including information on indications, posology and 
method of administration, pharmacodynamic and pharmacokinetic properties, possible side-effects 
related to driving and the DRUID risk category of individual medicines. The aim of these fact sheets 
was to provide healthcare professionals with appropriate information on possible effects of medicines 
on driving that could be easily used in their (risk) communication with patients.  
Even though some information is available, the problem of medicine-impaired driving remains 
complex. Physicians and pharmacists have to determine case-wise whether or not a particular patient 
will become an unsafe driver after using a specific psychotropic medicine. Practical guidelines with 
emphasis on prescribing and dispensing practices can assist the evaluation of the fitness to drive of 
patients undergoing medicinal treatment. Yet simple top-down dissemination of guidelines towards 
healthcare professionals alone has been proven ineffective (13-16). For example, previous research 
concluded that purely disseminating guidelines (among physicians) had a minor impact on the 
prescribing behaviour (17, 18). 
A more effective implementation strategy is the use of automatic computerised reminders in 
the daily used prescribing and dispensing software (19-21). Computerised reminders and alerts are an 
increasingly common means of delivering support to physicians and other healthcare professionals, 
and their use is likely to increase as electronic medical records are used more widely. Furthermore, 
computerised prompts and reminders are effective in changing the behaviour of healthcare 
professionals in a variety of settings (5, 22, 23). As pharmacists generally use a computer for 
dispensing, the potential of computerised decision-support for promoting clinical interventions that 
improve patient care and enhance pharmacists’ risk communication role is huge.  
Since October 2008 the Dutch government funded the development of a software-oriented 
support in dispensing pharmacy practices in the Netherlands. A categorisation system was made 
available in all Dutch pharmacy dispensing systems. Health Base Foundation supports further use of 
counselling information while dispensing medicines. In Belgium, one company (ESCAPO) uses the 
information provided by the Health Base Foundation as input for their dispensing support tool 
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‘ViaNova’. Apart from the ViaNova software different other dispensing software tools/databases are 
available in Belgium (e.g. Delphi care, Sofie (Farm@doc)) and Pharmawin) but they don’t contain 
specific information on the possible influence of a medicine on the driving.  
Aim of the study 
We implemented and evaluated two different types of dispensing support tools, one integrated into the 
existing ViaNova dispensing software and one as a stand-alone tool (USB stick), containing the 
guidelines, fact sheets and categorisation system developed by DRUID (11). The participating 
pharmacists received a training session and manual on how to use the provided tool as well as on the 
topic ‘medicines and driving’ in general (24). The aim of the study was to evaluate the effectiveness of 
training and six month implementation of the support tools on pharmacists’ awareness and attitudes, 
self-reported behaviour and knowledge. Secondly, the two different types of dispensing support tools 
were evaluated on user acceptance to identify which tool was the most successful and appreciated by 
the pharmacists, and most realisable in practice.  
Methods and materials 
Study design 
This study is a controlled prospective trial with 2 intervention groups and one control group. The first 
intervention group, further referred to as the integrated software group (IS), is a group of pharmacists 
using the ViaNova dispensing system in their daily practice (n=68). The second intervention group, 
further referred to as stand alone (SA) group (n=12), was a subgroup of the pharmacists from East 
Flanders (n=636), that installed a program containing the DRUID information on their work computer 
(25). In addition, a control group was added to evaluate the effectiveness of current practices with no 
DRUID-relevant information. Pharmacists in the IS and SA group were introduced to the tools/software 
through a training scheme. The participants filled in the pre-questionnaire at the start of their training 
and a post-questionnaire after six months of using the dispensing support tools in their practice. 
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 For the IS group the DRUID dispensing guidelines, fact sheets and categorisation system 
were integrated into the ViaNova software. When a pharmacist dispensed for example a category 3 
medicine for the first time, a warning sign (DRUID pictogram) automatically popped up indicating that 
driving is not allowed. If available, a safer alternative was proposed. When delivering the same 
medicine a second time the pharmacist was requested to ask about any side-effects encountered. The 
pharmacists had also the possibility to print out practical information letters for the patient.  
The second intervention group, SA group, install a program containing the DRUID information 
on their work computer (25). The program was delivered by means of a USB stick and had access to a 
website where all DRUID information was posted. When pharmacists opened the program they could 
type in the generic name or ATC code of the medicine they wanted to deliver. This tool clearly differs 
from the integrated software as pharmacists have to look up the guidelines and information separately 
(no automatic pop-up and no link with the patient). 
 Thirdly, the control group was a group of pharmacists from East Flanders (n=20). This group 
neither received training nor any dispensing support tool with access to the DRUID information 
 
Selection of pharmacists 
About one hundred pharmacists use the ViaNova software in their daily practice. In collaboration with 
ESCAPO participation was asked through email. For the SA and control group, a letter was sent to all 
pharmacists of East Flanders (n=636) including general study information, an invitation to follow a 
training session, the pre-questionnaire (prior to intervention), an informed consent form and a return 
envelope. These pharmacists were asked not to reply if they were ViaNova users. They were asked 
for their participation either in the SA group or the control group. These pharmacists could thus self-
select the group of participation (SA or control), although the letter also indicated that only the first 30 
respondents would be considered for following a training course (SA group) or would be selected for 
the control group. 
 
Training and questionnaire survey 
After the participants’ selection, the pharmacists in the IS and SA group were asked to complete the 
pre-questionnaire (baseline measurement) before the start of the training session. After that, the two 
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intervention groups followed a training and received a manual (24) on the support tool and on the topic 
‘medicines and driving’. During the training (3hours) the pharmacists were informed about the DRUID 
project and the aim of the study. The legal aspects of driving under the influence in Belgium and the 
role of pharmacists related to that were underlined. Finally the pharmacists were confronted with 
practical situations and examples. A step-by-step plan on how to activate and use the information 
integrated in the tools was provided. During the study newsletters with information on the topic 
‘medicines and traffic’ were sent by email to all participants in order to keep the topic under the 
attention of the pharmacists. After a six-month intervention period during which the DRUID information 
was available, the intervention as well as the control group participants were asked to complete the 
post-questionnaire. Table 1 gives an overview of the collected information in the pre- and post-
questionnaire (26). 
 
Ethical approval 
The study was approved by the Ethics committee of Ghent University Hospital. No patient information 
was collected. The privacy of the patient was guaranteed throughout the whole study. The 
pharmacists were free to refuse participation in the study or could terminate their cooperation at any 
time. All participants signed an informed consent form. The participants received a voucher incentive 
with value of 100€ for the IS and SA group and 25€ for the control group. 
 
---Table 1--- 
 
Statistical analysis  
SPSS version 19 was used for the data analysis. Due to sample size restrictions and variables’ scales, 
robust non-parametric analyses were used (significance level at p≤.05; 95% confidence interval). The 
attitudes & awareness and the reported behaviour composite scores were calculated based on the 
median score. A composite score integrates all single responses and gives an overall evaluation of a 
cluster. The knowledge composite score was calculated based on the sum of correct answers. Pre-
post significant differences were checked with the Wilcoxon matched pairs - signed-rank test. For the 
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sum composite score of knowledge, paired samples t-test was used for the IS group (not in the other 
groups because of sample size restrictions).  
Results 
 
Sample characteristics 
 
Except for the number of inhabitants in the practice area the three groups did not differ significantly 
regarding personal or practice related background variables (see Table 2). The pharmacists in the IS 
group had their practice significantly more often in more populated areas (>10,000 inhabitants) 
(p≤.05).  
 
---TABLE 2--- 
 
The participation rate was about 80% in the IS group, 80.0% in the SA group and 77.8% in the 
control group (see Figure 1). Twenty-eight pharmacists dropped out of the study (IS: 16, SA: 6, 
control: 6). There were no significant differences between participants and drop-outs in the SA and 
control group with regard to background variables and ICT familiarity. The IS dropped-out group 
seemed to be relatively younger (below 30), with less practicing years and more often working in a 
rural setting (p≤.05). Reasons for not participating in the study were time restrain, fear of 
incompatibility between their own software and the stand alone tool or not available on one of the 
evenings when the training sessions were given. 
 
--- FIGURE 1--- 
Effects on pharmacists’ attitudes/awareness, reported behaviour and knowledge 
Attitudes and awareness 
The majority of the pharmacists in all groups reported similar attitudes and awareness concerning 
driving under the influence of medicines before and after the six month intervention (see Table 3). 
Only one significant positive pre-post change was measured, in the IS group. On the question ‘I feel 
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that I am well aware of the effects of medicines on driving skills’, 25% of the pharmacists changed 
their answer in the positive sense (p=.048), which indicates that they felt more aware of the effect of 
medicines on driving skills after the training and using the DRUID information integrated in their 
software. No significant changes were found within the SA and control group. 
Reported behaviour 
A significant positive change was found on 7 of the 8 reported behaviour questions after the training 
and intervention phase of the IS participants (see Table 3). When medicines with impairing effects on 
driving were to be dispensed, significantly more pharmacists using the IS reported in the post-
questionnaire asking patients about their driving experience (Z= -5,207; p<.001), informing them about 
the driving related risks (Z= -5.443; p<.001) and discussing the medicine consumption and driving-
related responsibilities (Z=-5.231; p<.001). After the intervention, pharmacists also indicated that they 
provided detailed information on impairing effects of medicines more frequently (Z= -5.733; p<.001), 
and to keep records when dispensing such medicines (Z= -4.611; p<.001), when giving advice to 
patients (Z= -5.198, p=0), and about patients’ traffic participation (Z= -3.589; p<.001). The proportion 
of pharmacists informing patients regularly or always about risks increased up to almost the maximum. 
Furthermore, most answers shifted from pre-level ‘seldom to sometimes’ to post-level ‘sometimes to 
regular’ (asking about driving exposure, discussing responsibilities, frequency of detailed informing). 
With regard to record keeping when dispensing risky medicines or when giving advice, this seemed to 
be clearly done more often, but still quite a big group of pharmacists indicated doing this never or 
seldom.  
Only one significant positive change after the intervention was found in the SA group. 
Significantly more pharmacists (50%) reported to sometimes or regularly discuss medicine 
consumption and driving-related responsibility issues with the patient (Z=-2.333; p=.02).  
Knowledge 
With regard to pharmacists’ obligations and patients’ responsibilities no big changes were 
found. The answers in the pre-questionnaire were already predominantly correct. Rather limited pre-
post change was found on knowledge of individual medicinal risks on driving (see Table 3). This 
knowledge remained at a low level even after six months intervention. No significant changes were 
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found in the control group. In the SA group only one significant positive change was found, related to 
the risk of amitriptyline (Z=-2.00; p=.046). On this question there were fewer ‘don’t know’ answers (-
25%) and an increase of 33% answering correctly. Almost 60% (compared to 25%) answered this 
question correctly in the post-questionnaire.  
The best results were found in the IS group. Significantly more pharmacists in this group gave 
correct answers on the question about diazepam (Z=-2.200; p=.028) and amitriptyline (60% correct; 
Z=-2.744; p.006). For both questions there were also fewer ‘don’t know’ answers; this shift was the 
case in all medicinal risk related questions. One third of the pharmacists gave more correct answers 
(50% correct) on the question on codeine after the intervention (Z= -1,859; p=.063). Although the pre-
post change was mainly directed as expected, the number of incorrect or don’t know answers in the 
post-questionnaire remained quite high overall and for some questions this was the majority: 
paroxetine (70%) and diazepam (67%). 
 
---TABLE 3--- 
Composite scores 
Table 4 gives an overview of the changes found in the three clusters on composite score level. 
Significant pre-post changes were only found in the IS group. This group reported significantly more 
behavioural consideration of medicinal driving risk in their practice (risk communication and record 
keeping) (Z=-6.143; P<.001) and had a significant increase in knowledge of specific medicinal risk and 
legal responsibilities (Z= -2.511; p=.012). For the cluster ‘attitudes and awareness’ no significant 
change was found in any of the groups.  
 
---TABLE 4--- 
 
Evaluation of the dispensing support tools 
The user acceptance of the dispensing guidelines (e.g. ‘do not drive 8 hours after intake of zolpidem 
≤10mg’), and the information integrated in the ViaNova software were high (see Table 5). About 95% 
of the pharmacists indicated to have used the guidelines in their communication to the patients, of 
which 84% at least regularly. The clear majority found the guidelines helpful, useful and sufficient. On 
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the other hand, the pharmacists noted a low use of the fact sheets and the pictogram system (10-
20%).  
More than half of the pharmacists using the integrated software stated that the software with 
the guidelines changed the manner they dispensed medicines, and 60% mentioned that the guidelines 
changed ‘quite a lot’ up to ‘very much’ their way to inform a patient. Up to 90% of the pharmacists 
(strongly) agreed that they could find the information without difficulties and that the tool would fit well 
in their working routines. The texts and icons (pictograms) were easy to perceive. Some pharmacists 
mentioned that the tool should provide more thorough information on side-effects or less vague 
advice. The majority of the participants (80%) were willing to use the tool in the future. 
Analysis of the data extracted from the stand alone tool showed that the pharmacists seldom 
used the provided software because the tool was too time-consuming, not easy to use and contained 
too vague information. Taken all data together, only 1 search was made every four days (527 
searches on 180 days*N=12). In contrast with the negative evaluation of the tool itself, the provided 
dispensing guidelines were considered helpful, useful and sufficient by more than 80%. They stated 
that they would have used the tool more often if it was integrated into their daily used software.  
 
---TABLE 5--- 
 
Discussion 
The aim of the study was to evaluate the effectiveness of training and six months implementation of 
two dispensing support tools (integrated software and a stand alone tool) on pharmacists’ awareness 
and attitudes, self-reported behaviour and knowledge regarding driving impairing medicines. Most 
significant positive intervention effects were found within the IS group, who had the DRUID information 
integrated into their daily used software. In total 10 significant positive changes (on a total of 20 items) 
were found, compared to just 2 in the SA group. As expected there was no significant evolution in the 
control group, suggesting that the changes observed in the intervention groups are related to the 
intervention.  
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Little change on attitude was found in the intervention groups. The IS group did indicate a 
significant increase in awareness of the problem after the intervention and also in the SA group a 
positive evolution was observed in awareness although this was not statistically significant. 
Nevertheless, 43% in the IS group and 50% in the SA group still didn’t feel well-aware of the topic after 
the intervention. This small change on attitude is probably related to the already rather positive 
attitudes they had prior to the intervention. At the start of the study the participants indeed firmly 
underlined the importance of being well informed and aware of the possible risks of medicines on 
driving. The self-selection bias in the participant recruitment may have led to over-rated positive 
attitude and awareness prior the intervention and training. Nevertheless, as this bias accounts for the 
three groups, and as no significant difference in prior attitude between the groups was found, the 
between-group differences can be considered valid.  
The integrated information in the daily used software had an effect on the reported behaviour 
of the pharmacists using the integrated software. These participants were significantly more 
considerate of the problem on 7 of the 8 reported behaviour questions, as compared to only one 
significant positive change in the SA group. After the training and use of the tool for six months 
significantly more pharmacists had attention for the fact that their patients participate in traffic and 
informed them more about potential risks when taking a specific medicine.  
The pharmacists recognised that they have an important role in advising patients, certainly in 
case of patients receiving prescriptions from different physicians, as they have a good overview of all 
medicines taken. The DRUID pictogram can help the pharmacists in their risk communication towards 
a patient. These pictograms were already positively evaluated by patients in another study (27). The 
pharmacists noted that informing family members, who come to collect the prescribed medicines, can 
be difficult. A lot of information is lost when the communication was not directly with the patient. This 
problem may be partially overcome by introducing a pictogram on the medicine box.  
The number of incorrect or ‘don’t know’ answers to the knowledge questions remained quite 
high after training and intervention. In contrast with the low knowledge on individual medicine risk, the 
basic knowledge on legal pharmacists’ obligations and patient responsibilities was generally good 
already prior to the intervention. Therefore, few pre-post changes were found on this aspect. In 
general, the highest increase in knowledge was found in the pharmacists from the IS group.  
13 
 
The user acceptance of the provided information in the daily use software was high. The 
majority of the pharmacists using the integrated software found the dispensing guidelines helpful, 
useful and sufficient. The majority also reported though not to have used the fact sheets and the 
pictograms, but this was probably partly related to confusing terminology in the questionnaire with 
regard to what fact sheet and pictogram referred to. The term ‘fact sheet’ was not used in the 
integrated software, hence there is a possibility that pharmacists did read the text/fact sheet but did 
not mention this in the questionnaire. Moreover, the pictogram integrated in the software was rather 
small and could be easily ‘looked over’. Consequently, the pharmacists did not recall to have seen 
‘fact sheets’ or ‘pictograms’, resulting in low reported use.!! 
The pharmacists who used the stand alone tool found it too time-consuming and not easy to 
use which resulted in limited use. The clear first choice of all the pharmacists was information 
integrated in their software, followed by a website. These findings are in line with previous research 
(5). In order to be effective, the prompt should be part of the workflow, as close as possible to the 
decision moment and should be linked to supporting material to help increase the pharmacist’s 
knowledge (5, 23). A recent review showed that the use of information is compromised if it could not 
be integrated with existing systems (28). Finally, several studies describe the danger of desensitization 
to alerts. This effect is greatest when prompts are perceived as repetitious, time-consuming and not 
relevant to the decision at hand (5, 29, 30).  
Based on pharmacists’ feedback and the experiences in this study, three critical points can be 
mentioned to increase knowledge and sustain a positive attitude and awareness of pharmacists: keep 
the topic under the attention of the pharmacists, education and collaboration with physicians. First, to 
keep the topic under the attention of the pharmacists, newsletters proved very useful in the present 
study. In general, newsletters or other direct media may help to keep the topic under the attention of 
pharmacists. Furthermore, collaboration between pharmacists and physicians is needed to optimise 
the risk communication to the patient. The participating pharmacists stressed the importance of a 
shared responsibility. However, in reality there is often a difficult cooperation between physicians and 
pharmacists in Belgium. Thirdly, some pharmacists were unsure if pharmacy assistants, who often 
work under supervision of a pharmacist in Belgium, are educated enough to give advice about the 
influence of medicines on the driving abilities. Other studies also underlined the importance of a good 
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training or education in order to realise a change in attitude and behaviour in health professionals (28, 
30, 31).  
It is furthermore highly recommended that computerised alerts and reminders for selecting the 
safest medicine or for getting important risk information are presented automatically as part of the 
usual workflow. In order to optimise the risk communication between pharmacists and patients the 
information should be updated regularly and automatically, be easy to use, focus on first deliveries, be 
cost- and time-efficient, contain detailed information and (if possible) safer alternatives. The 
dispensing support tool should show suggestions on how to act at the time of dispensing and include 
practical advice for the patient on how to use the medicine at the start of treatment or in case of 
chronic use when driving is intended. A combination of tools, ideally integrated software and a manual 
or a website, is recommended. 
Limitations of the study 
It is essential to note that this was a small-scale and time-limited study with a rather few participating 
pharmacists, especially in the SA and control group. This might have affected the results. The found 
positive effects of the dispensing support tools are suggestive and would need to be confirmed in 
larger study designs. 
The study design initially took care that each participant had a unique identification code in 
order to link the individual questionnaire and software data. However, since many of the participants 
worked in pharmacies with several pharmacists using the same computer, the software data were not 
individual and could thus not be linked to the questionnaire data. 
Approximately half of the participating pharmacists were older than 46 years. Younger 
pharmacists found it less hard to install the stand alone tool. It is not unlikely that the older 
pharmacists were less inclined to use the stand alone tool when experiencing problems in installation 
or use, which could have resulted in a low use of this tool.  
Conclusions 
Almost all pharmacists involved in the present study underlined the importance of being informed on 
the potential risk of medicines on driving, yet they couldn’t readily access relevant information. The 
information developed by the DRUID project (medicinal risk categories for driving, individual medicine 
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fact sheets, dispensing guidelines) could fill the gap. The present study indicated that making such 
information available within the daily used dispensing software, in an automatically prompting way, 
can lead to more considerate behaviour as well as increased awareness of the potential impairing 
effects of certain medicines. 
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 Table 1. Pre- and post-questionnaire items 
A. Background information (6 items) 
Basic demographic, educational, practice background and expertise. 
B. New technologies literacy (7 items) 
Familiarity with internet and software tools in general and on medicinal effects on driving.  
C. Attitudes & Awareness (6 items) 
Opinions on dispensing medicines and driving. 
D. Reported behaviour (8 items) 
Reports of conducts that take medicinal effects on driving into account in daily practice. 
E. Sources (4 items) 
Current sources of information and knowledge on the topic. 
F. Actual knowledge (7 items) 
Acquired knowledge on medicine’s effects on driving and on legal responsibilities 
G. User acceptance (pre-3 items) 
Willingness to use a dispensing support tool with information for driving prior to the intervention. 
H. User acceptance (post tool-23 items) 
Acceptance of the content and functionalities of the tool after the intervention. 
I. Future use of the tool (post tool-3 items) 
Willingness to use the tool further.  
 Table 2 Description of study participants (within-group %) 
  
Integrated 
software 
Stand alone 
tool  Control  Total  
Gender Male  33.8 58.3 40.0 38.0 
  Female 66.2 41.7 60.0 62.0 
Age (years) <30  10.3 0.0 20.0 11.0 
  30-45  42.6 66.7 40.0 45.0 
  46-55  29.4 33.3 25.0 29.0 
  56-65  17.6 0.0 15.0 15.0 
Inhabitants in the practice area * >10000 89.2* 41.7 55.0 76.3 
  <10000 10.8* 58.3 45.0 23.7 
Year of graduation  60ies 1.5 0.0 0.0 1.0 
  70ies 22.1 0.0 20.0 19.0 
  80ies 32.4 41.7 25.0 32.0 
  90ies 27.9 33.3 35.0 30.0 
  ≥2000 16.2 25.0 20.0 18.0 
Years practising as pharmacist <5 y 10.4 0.0 10.0 9.1 
  5-10 y 6.0 25.0 10.0 9.1 
  11-15 y 14.9 25.0 15.0 16.2 
  16-20 y 16.4 16.7 35.0 20.2 
  >20 y 52.2 33.3 30.0 45.5 
no 82.1 83.3 68.4 79.6 Education on medicinal effects on 
driving skills during studies at 
University yes 17.9 16.7 31.6 20.4 
* Pearson Chi-Square p≤.05  
 Table 3 Pre-post within-group change (Wilcoxon Signed Ranks Test) 
 Integrated 
software 
Stand 
alone 
tool 
Control 
ATTITUDES AND AWARENESS*    
I am willing to take into account the effects of medicines on 
driving skills when dispensing medicines 
Z=-.398 
p=.691 
Z=000 
p=1 
Z= -.378 
p=.705 
I am willing to sacrifice some degree of efficacy by dispensing 
a medicine that is less impairing to the driving skills 
Z=-.943 
p=.346 
Z=1.000 
p=.317 
Z= -.333 
p=.739 
I feel being well aware of the effects of medicines on driving 
skills 
Z=-1.980 
p=.048 
Z=-1.000 
p=.317 
Z= -1.414 
p=.157 
It is important for me to be well-informed on medicinal effects 
on driving behaviour 
Z= -.756 
p=.450 
Z=-1.000 
p=.317 
Z= .000 
p=1 
I feel that the information I provide to patients will influence 
their driving behaviour 
Z= -1.616 
p=.106 
Z=-.577 
p=.564 
Z= -.577 
p=.564 
REPORTED BEHAVIOUR**    
I ask a patient about his/her driving exposure when dispensing 
a medicine 
Z= -5,207 
p<.001 
Z=-1.561 
p=.119 
Z= -.486 
p=.627 
I inform a patient about driving related risks when dispensing a 
medicine 
Z= -5.443 
p<.001 
Z= -.378 
p=.705 
Z= -1.941 
p=.052 
I provide a patient with written information materials when 
dispensing a driving impairing medicine 
Z= -.310  
p=.757 
Z= -.552 
p=.581 
Z= -1.98 
p=.272 
I keep systematic records when I dispense a driving impairing 
medicine 
Z= -4.611 
p<.001 
Z= -1.000 
p=.317 
Z=.000 
p= 1 
I keep systematic records when I advise a patient when and 
how he/she can consider driving a car when using a driving 
impairing medicine 
Z= -5.198 
p<.001 
Z=-.577 
p=.564 
Z= -.447 
p=.655 
I keep a record of the patient's traffic participation (e.g. how 
often he/she drives to work) 
Z= -3.589 
p<.001 
Z= -5.77 
p=.564 
Z= -.632 
p=.527 
I discuss medicine consumption and driving related 
responsibility issues with the patient 
Z=-5.231 
p<.001 
Z= -2.333 
p=.02 
Z= -1.645 
p=1 
How frequently do you usually provide detailed information 
when dispensing a medicine with impairing effects on driving 
performance 
Z=-5.733 
p<.001 
Z= -.577 
p=.564 
Z= -934 
p=.351 
KNOWLEDGE***    
Diazepam (regardless of dose) is severely impairing within the 
first 2 months of treatment  
Z=-2.200 
p=.028 
Z=-1,000 
p=.317 
Z=-1.890 
p=.059 
Codeine (up to 20 mg) is mostly safe for drivers  Z= -1,859; 
p=.063 
Z=-,447 
p=.655 
Z=-,816 
p=.414 
Fexofenadine (normal dose) is severely impairing driving Z= -.180 
p=.857 
Z=-1,414 
p=.157 
Z=-1,000 
p=.317 
Amitriptyline at the start of treatment is as impairing driving as 
after 4 weeks of treatment  
Z=-2.744 
p=.006 
Z=-2.00 
p=.046 
Z=-1,134 
p=.257 
Paroxetine (up to 20 mg/day) is safe for drivers Z=-1,342 
p=.180 
Z=-1,134 
p=.257 
Z=-1,265 
p=.206 
Pharmacists are obliged to inform the patients about the 
possible side effects of his/her medicines on driving abilities. 
Z=-,258 
p=.796 
Z=-1.732 
p=.083 
Z=,000 
p=1,000 
A patient can be punished with criminal sanctions if he causes 
a traffic accident while using a medicine with impairing 
Z=-1,387 
p=.166 
Z=-1,000 
p=.317 
Z=-1,000 
p=.317 
properties whereas the healthcare provider has advised him 
not to drive 
Significant results (p≤.05) 
* Answer categories: 1=Strongly agree; 2=Agree; 3=Disagree; 4=Strongly disagree 
** Answer categories: 1=Never; 2=Seldom; 3=Sometimes; 4=Regularly; 5=Always 
*** Answer categories: 1=Totally disagree; 2=Disagree; 3=Neutral; 4=Totally agree; 5=I do not know 
 
 Table 4. Total group overview of pre-post changes: Composite scores 
 Composite scores 
Integrated software 
group 
(within-group %) 
Composite scores  
stand alone tool group 
(within-group %) 
Composite scores 
Control group 
(within-group %) 
 Pre Post Change Pre Post Change Pre Post Change 
Attitudes & awareness 
Strongly disagree  0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Disagree  10.3 11.8 1.5 8.3 0.0 -8.3 5.0 15.0 10.0 
Agree  86.8 83.9 -2.9 91.7 100 8.3 90.0 85.0 -5.0 
Strongly agree  2.9 4.4 1.5 0.0 0.0 0.0 5.0 0.0 -5.0 
Reported behaviour 
Never 13.2 1.5 -11.7* 8.3 0.0 -8.3 20.0 15.0 -5.0 
Seldom 48.5 10.3 -38.2* 41.6 33.4 -8.2 45.0 50.0 5.0 
Sometimes 32.4 48.5 16.1* 50 50.0 0.0 25.0 25.0 0.0 
Regular 5.9 32.3 26.4* 0.0 16.7 16.7 10.0 10.0 0.0 
Always 0 7.3 7.3* 0.0 0.0 0.0 0.0 0.0 0.0 
Knowledge  
0 4.4 0.0 -4.4* 0.0 0.0 0.0 0.0 0.0 0.0 
1 8.8 4.4 -4.4* 8.3 0.0 -8.3 0.0 0.0 0.0 
2 13.2 13.2 0* 16.7 16.7 0.0 10.0 15.8 5.8 
3 22.1 23.5 1.4* 16.7 33.3 16.6 25.0 15.8 -9.2 
4 35.3 20.6 -14.7* 41.7 25.0 -16.7 45.0 10.5 -34.5 
5 11.8 23.5 11.7* 8.3 25.0 16.7 20.0 31.6 11.6 
6 4.4 11.8 7.4* 8.3 0.0 -8.3 0.0 21.1 21.1 
7 0.0 2.9 2.9* 0.0 0.0 0.0 0.0 5.3 5.3 
*Significant results (p≤.05) 
 Table 5. User acceptance of the integrated and stand alone (USB stick) dispensing support tools 
 Integrated 
software (within 
group %) 
Stand 
alone tool 
(within 
group %) 
Yes 
Guidelines 95.60 91.7 
Fact sheet 10.30 33.3 
Did you use…in order to support your 
communication to patients? 
Pictogram 22.10 41.7 
Guidelines 84.9 25.0 
Fact sheet 28.6 60.0 
If you answered ‘yes’, did you regularly use 
the…? 
Pictogram 64.30 40.0 
Do you think the guidelines have changed your manner/way of 
dispensing medicines?* 
53.0 50.0 
Do you think that the guidelines have changed your manner/way to 
inform the patient?* 
60.3 75.0 
Were you able to find the information you asked for with no 
difficulties?** 
89.2 75.0 
Would you be willing to use this tool in the future? 80.0 50.0 
Use (yes)* 
Guidelines  95.6 91.7 
Helpful 92.7 91.7 
Useful 89.7 83.3 
 
Sufficient 85.3 75.0 
Fact sheet  10.3 33.3 
Helpful 22.0 66.6 
Useful 18.7 41.7 
 
Sufficient 20.6 50.0 
Pictograms  22.1 41.7 
Helpful 30.9 66.7 
Useful 33.8 66.7 
 
Sufficient 32.4 50.0 
* the ‘yes’ answer consists of the combined percentages of the ‘yes’ answers and the ‘quite a lot’ answers 
** the ‘yes’ answer consists of the combined percentages of the ‘agree’ answers and the ‘strongly agree’ answers 
 
 
  
Figure 1. Flow chart indicating the flow of the study sample size: from initial participant recruitment to full study 
participation 
